Safety and efficacy of sugammadex in management of patients with myasthenia gravis undergoing general anesthesia: A systematic review
Objective: The objective of this study was to analyze available evidence on efficacy and safety of sugammadex in reversing neuromuscular blockades in patients with Myasthenia Gravis (MG), thereby providing a comprehensive understanding of its potential benefits and risks in this specific patient pop...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844025001379 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832573148708470784 |
|---|---|
| author | Alan D. Kaye Emily A. Villafarra Erin S. Everett Erin E. Ware Sydney A. Mashaw William D. Brouillette Camille G. Elder Taylor Moss Luke Muiznieks Edwin Herron Shahab Ahmadzadeh Sahar Shekoohi |
| author_facet | Alan D. Kaye Emily A. Villafarra Erin S. Everett Erin E. Ware Sydney A. Mashaw William D. Brouillette Camille G. Elder Taylor Moss Luke Muiznieks Edwin Herron Shahab Ahmadzadeh Sahar Shekoohi |
| author_sort | Alan D. Kaye |
| collection | DOAJ |
| description | Objective: The objective of this study was to analyze available evidence on efficacy and safety of sugammadex in reversing neuromuscular blockades in patients with Myasthenia Gravis (MG), thereby providing a comprehensive understanding of its potential benefits and risks in this specific patient population. Methods: We performed a systematic search for studies from PubMed, Embase, Web of Science, and Google Scholar. Sources were screened using Rayyan, following predefined inclusion and exclusion criteria focusing on English articles published from 2010 to 2024 on MG patients under general anesthesia. Data on patient characteristics and outcomes were extracted, and quality was appraised using the JBI Critical Appraisal Checklist. Results: Out of 361 initial citations, 24 studies met inclusion criteria. Sugammadex demonstrated rapid and effective reversal of neuromuscular blockades, with ToF recovery times ranging from 79.7 s to 10 min, and short extubation times. The incidence of postoperative myasthenic crisis was low, and no mortalities were reported. Conclusion: Sugammadex may serve as a reasonable option for the reversal of neuromuscular blockades in MG patients, indicating potential for rapid recovery and a relatively low incidence of serious complications. However, due to the limited number of studies and the nature of the evidence available, further large-scale and rigorous investigations are warranted to better establish its superiority over traditional reversal agents. |
| format | Article |
| id | doaj-art-68d6646ef72e4bd4adfad7c454e6bb19 |
| institution | Kabale University |
| issn | 2405-8440 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj-art-68d6646ef72e4bd4adfad7c454e6bb192025-02-02T05:28:06ZengElsevierHeliyon2405-84402025-01-01112e41757Safety and efficacy of sugammadex in management of patients with myasthenia gravis undergoing general anesthesia: A systematic reviewAlan D. Kaye0Emily A. Villafarra1Erin S. Everett2Erin E. Ware3Sydney A. Mashaw4William D. Brouillette5Camille G. Elder6Taylor Moss7Luke Muiznieks8Edwin Herron9Shahab Ahmadzadeh10Sahar Shekoohi11Departments of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, 71103, USASchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USASchool of Medicine, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA, 70112, USASchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USASchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USASchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USASchool of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USADepartment of Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, 71103, USADepartment of Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, 71103, USADepartment of Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, 71103, USADepartment of Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, 71103, USADepartment of Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, 71103, USA; Corresponding author. Department of Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, 71103, USA.Objective: The objective of this study was to analyze available evidence on efficacy and safety of sugammadex in reversing neuromuscular blockades in patients with Myasthenia Gravis (MG), thereby providing a comprehensive understanding of its potential benefits and risks in this specific patient population. Methods: We performed a systematic search for studies from PubMed, Embase, Web of Science, and Google Scholar. Sources were screened using Rayyan, following predefined inclusion and exclusion criteria focusing on English articles published from 2010 to 2024 on MG patients under general anesthesia. Data on patient characteristics and outcomes were extracted, and quality was appraised using the JBI Critical Appraisal Checklist. Results: Out of 361 initial citations, 24 studies met inclusion criteria. Sugammadex demonstrated rapid and effective reversal of neuromuscular blockades, with ToF recovery times ranging from 79.7 s to 10 min, and short extubation times. The incidence of postoperative myasthenic crisis was low, and no mortalities were reported. Conclusion: Sugammadex may serve as a reasonable option for the reversal of neuromuscular blockades in MG patients, indicating potential for rapid recovery and a relatively low incidence of serious complications. However, due to the limited number of studies and the nature of the evidence available, further large-scale and rigorous investigations are warranted to better establish its superiority over traditional reversal agents.http://www.sciencedirect.com/science/article/pii/S2405844025001379Myasthenia gravisNeuromuscular diseaseNeuromuscular blockadeReversalSugammadexNeostigmine |
| spellingShingle | Alan D. Kaye Emily A. Villafarra Erin S. Everett Erin E. Ware Sydney A. Mashaw William D. Brouillette Camille G. Elder Taylor Moss Luke Muiznieks Edwin Herron Shahab Ahmadzadeh Sahar Shekoohi Safety and efficacy of sugammadex in management of patients with myasthenia gravis undergoing general anesthesia: A systematic review Heliyon Myasthenia gravis Neuromuscular disease Neuromuscular blockade Reversal Sugammadex Neostigmine |
| title | Safety and efficacy of sugammadex in management of patients with myasthenia gravis undergoing general anesthesia: A systematic review |
| title_full | Safety and efficacy of sugammadex in management of patients with myasthenia gravis undergoing general anesthesia: A systematic review |
| title_fullStr | Safety and efficacy of sugammadex in management of patients with myasthenia gravis undergoing general anesthesia: A systematic review |
| title_full_unstemmed | Safety and efficacy of sugammadex in management of patients with myasthenia gravis undergoing general anesthesia: A systematic review |
| title_short | Safety and efficacy of sugammadex in management of patients with myasthenia gravis undergoing general anesthesia: A systematic review |
| title_sort | safety and efficacy of sugammadex in management of patients with myasthenia gravis undergoing general anesthesia a systematic review |
| topic | Myasthenia gravis Neuromuscular disease Neuromuscular blockade Reversal Sugammadex Neostigmine |
| url | http://www.sciencedirect.com/science/article/pii/S2405844025001379 |
| work_keys_str_mv | AT alandkaye safetyandefficacyofsugammadexinmanagementofpatientswithmyastheniagravisundergoinggeneralanesthesiaasystematicreview AT emilyavillafarra safetyandefficacyofsugammadexinmanagementofpatientswithmyastheniagravisundergoinggeneralanesthesiaasystematicreview AT erinseverett safetyandefficacyofsugammadexinmanagementofpatientswithmyastheniagravisundergoinggeneralanesthesiaasystematicreview AT erineware safetyandefficacyofsugammadexinmanagementofpatientswithmyastheniagravisundergoinggeneralanesthesiaasystematicreview AT sydneyamashaw safetyandefficacyofsugammadexinmanagementofpatientswithmyastheniagravisundergoinggeneralanesthesiaasystematicreview AT williamdbrouillette safetyandefficacyofsugammadexinmanagementofpatientswithmyastheniagravisundergoinggeneralanesthesiaasystematicreview AT camillegelder safetyandefficacyofsugammadexinmanagementofpatientswithmyastheniagravisundergoinggeneralanesthesiaasystematicreview AT taylormoss safetyandefficacyofsugammadexinmanagementofpatientswithmyastheniagravisundergoinggeneralanesthesiaasystematicreview AT lukemuiznieks safetyandefficacyofsugammadexinmanagementofpatientswithmyastheniagravisundergoinggeneralanesthesiaasystematicreview AT edwinherron safetyandefficacyofsugammadexinmanagementofpatientswithmyastheniagravisundergoinggeneralanesthesiaasystematicreview AT shahabahmadzadeh safetyandefficacyofsugammadexinmanagementofpatientswithmyastheniagravisundergoinggeneralanesthesiaasystematicreview AT saharshekoohi safetyandefficacyofsugammadexinmanagementofpatientswithmyastheniagravisundergoinggeneralanesthesiaasystematicreview |